Skip to content
IDSA Foundation
  • AboutExpand
    • Why ID Medicine?
    • Our People
    • Our Individual Donors
    • Your Health PlatformExpand
      • Dr. John G. Bartlett Memorial Education Series
      • Infectious Diseases A to Z
    • Newsletter Archives
    • Annual Reports
    • Financials
  • GivingExpand
    • Industry Partners
    • Make a One-Time Gift
    • Give Monthly as an ID Detective
    • Join the Leadership Society
    • Join the Visionary Society
    • Make a Memorial or Tribute Gift
    • Foundation Naming Opportunities
    • Planned Giving
  • Careers in IDExpand
    • ID Career Paths
  • Fellowships, Grants & ProgramsExpand
    • AMR Education Grants
    • Dr. John G. Bartlett Memorial Education Series
    • G.E.R.M. Program
    • HIVMA Clinical Fellowship Program
    • IDea Incubator
    • ID Student Interest Groups Grant Program
    • Microbial Pathogenesis in Alzheimer’s Disease Grant
    • IDWeek Mentorship Program
    • Women of ID Program
  • Blog
IDSA Foundation

Gilead Sciences

Gold INDUSTRY PARTNER

home > giving > industry partners

Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. For 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Visit Website
  • Resources

Community Stories@Gilead: Honoring the History and Impact of the AIDS Memorial Quilt (January 2023)

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Tx Option for PLWH w/MDR HIV 

Gilead Enables Easier Veklury® (remdesivir) Access Through Retail & Specialty Pharmacies for LTC & Skilled Nursing Facilities 

U.S. FDA Approves Vemlidy® (tenofovir alafenamide) for Tx of Chronic HBV Infection in Pediatric Patients

Contact:

Gilead Public Affairs 
Attn: Virology Lead
(650) 574-3000
(800) GILEAD-5 (800-445-3235)
public_affairs@gilead.com

Gilead.com

4040 Wilson Blvd, Suite 300
Arlington, VA 22203

TEL: 703.299.0200
FAX: 703.299.0204
EIN: 31-1765388

Subscribe

Stay up to date by subscribing to ID Insights, our monthly newsletter

Sign Up!

Helpful Links

  • Blog
  • Privacy Policy
  • Terms & Conditions
  • Donor Bill of Rights

© 2023 IDSA Foundation All Rights Reserved. // Moonlit Media.

Scroll to top
  • About
    • Why ID Medicine?
    • Our People
    • Our Individual Donors
    • Your Health Platform
      • Dr. John G. Bartlett Memorial Education Series
      • Infectious Diseases A to Z
    • Newsletter Archives
    • Annual Reports
    • Financials
  • Giving
    • Industry Partners
    • Make a One-Time Gift
    • Give Monthly as an ID Detective
    • Join the Leadership Society
    • Join the Visionary Society
    • Make a Memorial or Tribute Gift
    • Foundation Naming Opportunities
    • Planned Giving
  • Careers in ID
    • ID Career Paths
  • Fellowships, Grants & Programs
    • AMR Education Grants
    • Dr. John G. Bartlett Memorial Education Series
    • G.E.R.M. Program
    • HIVMA Clinical Fellowship Program
    • IDea Incubator
    • ID Student Interest Groups Grant Program
    • Microbial Pathogenesis in Alzheimer’s Disease Grant
    • IDWeek Mentorship Program
    • Women of ID Program
  • Blog
Search